Navigation Links
LeadingBiotech’s Boston CEO Conference Unites Biopharma Leaders May 28-29 at Four Seasons Hotel
Date:4/4/2019

LeadingBiotech, an exclusive event series bringing biopharma CEOs and leaders together through intimate off-the-record collaboration and dialogue, today announces its Boston CEO conference to be held May 28-29, 2019 at Boston’s Four Seasons Hotel. Boston CEO offers insights into the industry’s challenges and opportunities with high-level panels and discussions from past, present and future change-makers.

LeadingBiotech, formerly Boston Biotech Conferences, is moving in a new direction, creating a reinvigorated experience for senior leaders.

“Our CEO event series has evolved to offer an even better experience for our attendees to inform business strategies and set industry agendas,” explained LeadingBiotech CEO Wendy Nelson, Ph.D. “The event’s mission is to share ideas, compare experiences and speak candidly through off-the-record dialogue.”

Highlights of this year’s conference include a special fireside chat titled: Navigating A New Frontier in Biotech – what is the industry facing now and in the future? From consolidation in healthcare to the impact of med tech and data science on how medicines are consumed, the biotech industry is launching into a different world. The discussion offers insights into the question: In a time of seismic shifts and tremendous change, how do we make sure the cost of innovation also leads to better care? Featured speakers include Jeremy M. Levin, D.Phil, MB BChir,?Chairman & CEO, Ovid Therapeutics Ovid Therapeutics; Bruce Booth, D.Phil, Partner, Atlas Venture; and Andy Plump, M.D., Ph.D., President, R&D, Takeda Pharmaceutical Co., Ltd.

“I’m delighted to be a part of Boston CEO’s impressive lineup of discussions and look forward to participating in the fireside chat on industry change, innovation and the impact on patient care,” said Jeremy M. Levin, D.Phil, MB BChir, Chairman & Chief Executive Officer, Ovid Therapeutics. “Boston CEO is a great opportunity to collaborate with some of Boston’s key industry leaders.”

Keynote speakers at this year’s event include:

Jeff Jonas, M.D., Chief Executive Officer, Sage Therapeutics
Laurie Glimcher, M.D., President & CEO, Dana Farber Cancer Institute
George Church, Ph.D., Professor of Genetics, Department of Genetics, Harvard Medical School
Michael Sherman, M.D., Chief Medical Officer and Sr. VP, Harvard Pilgrim Health Care
John Glasspool - Chief Executive Officer, Anthos Therapeutics

Additional keynote and panel topics at the conference include:

A Digital Revolution: Biotech’s Convergence with Data Science
Building Effective Partnerships to Advance New Drugs
Keynote: Technologies for Reading & Editing Genomes
Exit Dynamics in 2019: M&As vs IPOs
Fireside Chat: Raising Money Non-Traditionally
Patient Engagement & Advocacy

Please find our complete agenda here: https://bit.ly/2GrYgNz

About LeadingBiotech
Formerly known as Boston Biotech Conferences, LeadingBiotech is an event series that brings biopharma CEOs and leaders together through intimate, off-the-record collaboration. We’re working hard to create more valuable experiences to re-energize collaboration and infuse fresh ideas to better shape the future of biotech. For more, please visit: https://leadingbiotech.com/.

Read the full story at https://www.prweb.com/releases/leadingbiotechs_boston_ceo_conference_unites_biopharma_leaders_may_28_29_at_four_seasons_hotel/prweb16216079.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Top Tech Companies to Showcase Latest in Artificial Intelligence at Open Data Science Conference in Boston May 2019
2. Newly Appointed CEO, Wendy Nelson, PhD, Leads Boston Biotech Conferences in a New Direction
3. InTouchMD to Exhibit at Biotech Week Boston, Showcase Pulse Platform
4. Create + Construct Comes to Boston to Focus on Advancing Health Care and Life Science Facilities
5. The HealthTech Venture Network Celebrates Innovation and Female Entrepreneurship at Fourth Annual Conference in Boston
6. Boston Strategic Partners, Inc. is Utilizing Electronic Health Record Data to Analyze Hospital Treated Pneumonia
7. PRC Clinical Partners With SDC to Expand ClinPulse Event Series to the Boston Biotech Hub
8. Boston Strategic Partners, Inc. is utilizing Electronic Health Record Data for real world data analysis
9. 4 Strategic Takeaways from Open Data Science Conference 2017 in Boston
10. Stratevi Expands to East Coast with Boston Office Opening
11. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2019)... ... April 16, 2019 , ... ... their project partner, the U.S. Army Center for Environmental Health Research (USACEHR), with ... Combined In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company located at the Frederick Innovative ...
(Date:4/10/2019)... ... April 10, 2019 , ... After more than three months ... new kitchen is equipped with updated appliances and modern lighting and fixtures, and will ... , “We’ve seen tremendous growth in the demand for our team-building events ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global Securities ... million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). , ... is targeted at female hypoactive sexual dysfunction disorder and is ready to begin phase ...
(Date:3/27/2019)... ... March 26, 2019 , ... A leader in the field of ... veterinarians across the United States and Canada since 2004. The primary indications for ... injuries in the dog, cat, and horse. Recently, VetStem teamed up with ...
Breaking Biology Technology:
(Date:4/9/2019)... ST. LOUIS (PRWEB) , ... April 09, 2019 ... ... cost, quality and clinical outcomes, today announced a new partnership with Ambry Genetics, ... its healthcare providers access to state-of-the-art clinical genetic testing and family history assessment, ...
(Date:4/4/2019)... ... 2019 , ... The live session taking place ... connectivity between product risk management (ISO 14971) and the clinical risk management process ... With increasing global regulation and reimbursement challenges faced by medical device companies, it ...
(Date:3/29/2019)... ... , ... In the development of biosimilars, the broad definition of the similarity ... this uncertainty, several manufacturers have been successful and numerous follow-on biologics are approved in ... learn how analytical similarity is achieved in biosimilars based on recently approved products in ...
Breaking Biology News(10 mins):